1. Home
  2. CRSP vs FRSH Comparison

CRSP vs FRSH Comparison

Compare CRSP & FRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • FRSH
  • Stock Information
  • Founded
  • CRSP 2013
  • FRSH 2010
  • Country
  • CRSP Switzerland
  • FRSH United States
  • Employees
  • CRSP N/A
  • FRSH N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • FRSH EDP Services
  • Sector
  • CRSP Health Care
  • FRSH Technology
  • Exchange
  • CRSP Nasdaq
  • FRSH Nasdaq
  • Market Cap
  • CRSP 4.9B
  • FRSH 4.5B
  • IPO Year
  • CRSP 2016
  • FRSH 2021
  • Fundamental
  • Price
  • CRSP $57.68
  • FRSH $13.57
  • Analyst Decision
  • CRSP Buy
  • FRSH Buy
  • Analyst Count
  • CRSP 16
  • FRSH 15
  • Target Price
  • CRSP $70.73
  • FRSH $20.20
  • AVG Volume (30 Days)
  • CRSP 3.7M
  • FRSH 4.8M
  • Earning Date
  • CRSP 08-04-2025
  • FRSH 07-29-2025
  • Dividend Yield
  • CRSP N/A
  • FRSH N/A
  • EPS Growth
  • CRSP N/A
  • FRSH N/A
  • EPS
  • CRSP N/A
  • FRSH N/A
  • Revenue
  • CRSP $37,675,000.00
  • FRSH $782,097,000.00
  • Revenue This Year
  • CRSP $28.31
  • FRSH $16.04
  • Revenue Next Year
  • CRSP $268.05
  • FRSH $12.59
  • P/E Ratio
  • CRSP N/A
  • FRSH N/A
  • Revenue Growth
  • CRSP N/A
  • FRSH 19.78
  • 52 Week Low
  • CRSP $30.04
  • FRSH $10.81
  • 52 Week High
  • CRSP $71.13
  • FRSH $19.77
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 52.32
  • FRSH 35.45
  • Support Level
  • CRSP $61.13
  • FRSH $13.89
  • Resistance Level
  • CRSP $69.58
  • FRSH $14.37
  • Average True Range (ATR)
  • CRSP 3.89
  • FRSH 0.49
  • MACD
  • CRSP -0.71
  • FRSH -0.07
  • Stochastic Oscillator
  • CRSP 28.46
  • FRSH 16.34

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About FRSH Freshworks Inc.

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.

Share on Social Networks: